Achillion Pharmaceuticals (ACHN)
Achillion Pharmaceuticals News
Too Little, Too Late for Achillion?
Fool about 4 days agoAchillion produces solid hepatitis C data, but competitors are out in front.
Achillion Announces Executive Promotion
GlobeNewswire about 9 days agoNEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. , a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion ...
6 Low-Debt Healthcare Stocks That Analysts Rate As Buy Or Better
about 9 days agoACHILLION PHARMACEUTICALS INC Financials
about 10 days agoHealthcare Business Recap: Johnson & Johnson Drops This Premature Ejaculation Drug
about 11 days agoAchillion gets FDA incentives for hepatitis C drug
about 12 days agoStocks to Watch: Groupon, Avon Products, Agilent Technologies
about 12 days agoUPDATE 1- Achillion's hepatitis C drug gets FDA fast track
about 12 days agoACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
Benzinga about 12 days ago5 of Last Week's Biggest Winners
Fool about 13 days agoThese stocks made longs a lot of money last week.
New Star Analyst Rankings for Achillion Pharmaceuticals, Inc.
about 17 days agoACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
about 17 days agoAchillion Pharmaceuticals, Inc. (ACHN) Tops Q1 EPS by 2c
Street Insider about 17 days agoAchillion Reports First Quarter 2012 Financial Results
GlobeNewswire about 17 days agoNEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. , a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results ...
Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
GlobeNewswire about 18 days agoNEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. today announced that it has begun dosing ACH-3102 in a Phase 1 clinical trial. ACH-3102 is Achillion's second generation pan-genotypic NS5A inhibitor ...
You may also be interested in these ACHN related companies
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ABB | 16.18 | -0.22 | -1.34% | 37.45B |
| ABAX | 32.56 | -0.02 | -0.06% | 706.23M |
| AB | 13.38 | -0.19 | -1.40% | 1.407B |
| AAXJ | 49.90 | -0.38 | -0.76% | |
| AAWW | 45.92 | -0.76 | -1.63% | 1.208B |
| AAV | 2.83 | -0.01 | -0.35% | 471.39M |
| AAU | 2.01 | -0.04 | -1.95% | 118.83M |
| AAPL | 562.29 | -3.03 | -0.54% | 524.26B |
| AAP | 73.67 | +0.74 | +1.01% | 5.373B |
